|
|
||||||||
Suppress It



*
Laboratory of Cellular and Clinical Immunology, Institut National de la Santé et de la Recherche Médicale Unité 255, Institut de Recherches Biomédicales des Cordeliers, Paris, France; and
Schering-Plough, Laboratory for Immunological Research, Dardilly, France
| Abstract |
|---|
|
|
|---|
/CCL20, a chemokine secreted by epithelial cells, induces
the selective migration of LC among DC populations. In this study, we
investigated the effects of cytokines on the expression of the CCL20
receptor, CCR6, during differentiation of LC. We found that both IL-4
and IFN-
blocked the expression of CCR6 and CCL20 responsiveness at
different stages of LC development. The effect of IL-4 was reversible
and most likely due to the transient blockade of LC differentiation. In
contrast, IFN-
-induced CCR6 loss was irreversible and was
concomitant to the induction of DC maturation. When other cytokines
involved in DC and T cell differentiation were tested, we found that
IL-10, unlike IL-4 and IFN-
, maintained CCR6 expression. The effect
of IL-10 was reversible and upon IL-10 withdrawn, CCR6 was lost
concomitantly to final LC differentiation. In addition, IL-10 induced
the expression of CCR6 and responsiveness to CCL20 in differentiated
monocytes that preserve their ability to differentiate into mature DC.
Finally, TGF-
, which induces LC differentiation, did not alter early
CCR6 expression, but triggered its irreversible down-regulation, in
parallel to terminal LC differentiation. Taken together, these results
suggest that the recruitment of LC at epithelial surface might be
suppressed during Th1 and Th2 immune responses, and amplified during
regulatory immune responses involving IL-10 and
TGF-
. | Introduction |
|---|
|
|
|---|
-producing cells (11, 12), and lymphoid-derived DC,
identified in mice, have been proposed to play a role in maintenance of
peripheral tolerance (3, 13). Finally, Langerhans cells
(LC) represent a population of DC only found in epithelia, and whose
specific function is not yet fully elucidated.
The selective recruitment of a specific DC population at the site of
infection will most likely be determinant for the type of immune
response initiated. Recently, we and others have observed that
macrophage-inflammatory protein-3
, also known as CCL20
(14), was the only chemokine produced by the epithelium
that selectively attracts LC precursors (15, 16). CCL20
has also been shown to selectively induce migration of memory T cells
with skin and gut epithelium-homing capacities as well as a
subpopulation of gut intraepithelial T lymphocytes
(17, 18, 19). Its unique activity suggests a key role of CCL20
in the control of LC and lymphocyte subset recruitment at epithelial
surfaces and in the regulation of epithelial immunity. The
understanding of the regulation of CCL20 secretion as well as of the
expression of its receptor, CCR6, during LC development, should open
avenues to understand and potentially control the specific function of
epithelial LC. In the present study, we have studied the effects of
IL-4, IFN-
, IL-10, and TGF-
, cytokines involved in T cell
(20, 21, 22, 23) and DC differentiation, on the expression of CCR6
during LC development.
Several studies have shown that LC are regulated independently
from other DC populations. In particular, TGF-
has been identified
as a mandatory factor for the development of LC both in vitro and in
vivo (24, 25, 26). In contrast, IL-4 that is required for the
development of DC from monocytes (27, 28) blocks the
development of LC from CD34+ hemopoietic
progenitor cells (HPC) (29). IL-10 has also been shown to
block DC development and maturation (30, 31, 32, 33). We found
that IL-4 and IFN-
block the expression of CCR6 as well as the
responsiveness to CCL20. TGF-
irreversibly down-regulates CCR6
expression during final LC differentiation. In contrast, IL-10
positively regulates CCR6 expression on
CD34+-derived precursor cells and differentiated
monocytes without affecting their capacity to differentiate into LC or
mature DC. These results suggest that during Th1 and Th2 responses,
IFN-
and IL-4 might prevent epithelial colonization by LC. During
mucosal-type immune responses, IL-10 might increase LC precursor
recruitment and TGF-
expressed at mucosal surfaces, and might arrest
LC when they reach epithelium.
| Materials and Methods |
|---|
|
|
|---|
Recombinant human GM-CSF (rhGM-CSF; sp. act., 2 x
106 U/mg; Schering-Plough Research Institute,
Kenilworth, NJ) was used at a saturating concentration of 100 ng/ml.
rhTNF-
(sp. act., 2 x 107 U/mg; Genzyme,
Boston, MA) was used at an optimal concentration of 2.5 ng/ml
(34). Recombinant human stem cell factor (rhSCF; sp. act.,
4 x 105 U/mg; R&D Systems, Abington, U.K.)
was used at an optimal concentration of 25 ng/ml. rhIL-4 (sp. act., 2
x 107 U/mg; Schering-Plough) was used at
a saturating concentration of 50 U/ml. rhIL-10 (sp. act.,
107 U/mg; Schering-Plough) was used at 100 ng/ml.
rhIFN-
(sp. act., 107 U/mg; Sigma-Aldrich, St.
Louis, MO) was used at 20 ng/ml. rhTGF-
1 (sp. act., 5 x
107 U/mg; R&D Systems) was used at 10 ng/ml. LPS
(Sigma-Aldrich) was used at 10 ng/ml. Recombinant human chemokines
macrophage-inflammatory protein-3
/CCL20 (sp. act., 4 x
105 U/mg) and monocyte chemoattractant
protein-3/CCL7 (sp. act., 1 x 104 U/mg)
were obtained through R&D Systems. mAbs against Langerin (clone
DC-GM4) (35) and E-cadherin (clone HECD-1; Takara
BioWhittaker Europe) were used to characterize LC. The
maturation state of DC was determined by using the following mAbs:
anti-CD83 (Immunotech, Marseille, France), anti-CD86 (BD
PharMingen, San Diego, CA), and anti-DC LAMP (clone 104.G4)
(36).
Generation of DC from cord blood CD34+ HPC
Umbilical cord blood samples were obtained according to institutional guidelines. Cells bearing CD34+ Ag were isolated from mononuclear fractions through positive selection, as described (34, 37), using anti-CD34+ mAb (Immu-133.3; Immunotech), goat anti-mouse IgG-coated microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), and Minimacs separation columns (Miltenyi Biotec). In all experiments, the isolated cells were 8099% CD34+. After purification, CD34+ cells were cryopreserved in 10% DMSO.
Cultures were established in the presence of GM-CSF, TNF-
, and SCF,
as described (34), in endotoxin-free medium consisting of
RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10%
(v/v) heat-inactivated FBS (Flow Laboratories, Irvine, U.K.), 10 mM
HEPES, 2 mM L-glutamine, 5 x
10-5 M 2-ME, and 100 µg/ml gentamicin
(Schering-Plough) (referred to as complete medium). After thawing,
CD34+ cells were seeded for expansion in 25- to
75-cm2 culture vessels (Linbro; Flow
Laboratories) at 2 x 104 cells/ml. Optimal
conditions were maintained by splitting these cultures at days 5 and 10
with medium containing fresh GM-CSF with or without other cytokines
(cell concentration: 13 x 105 cells/ml).
At day 12, between 70 and 90% of the cells are
CD1a+ DC in GM-CSF condition.
Generation of DC from peripheral blood monocytes
Monocytes were purified by immunomagnetic depletion (Dynabeads; Dynal Biotech, Oslo, Norway) after preparation of PBMC, followed by a 52% Percoll gradient. The depletion was performed with anti-CD3 (OKT3), anti-CD19 (4G2), anti-CD8 (OKT8), anti-CD56 (NKH1; Beckman Coulter, Palo Alto, CA), and anti-CD16 (ION16; Immunotech) mAbs. Monocytes were cultured for 67 days in the presence of GM-CSF and IL-4 for the generation of DC (27) or in presence of GM-CSF plus IL-10 with or without IL-4 (cell concentration: 13 x 105 cells/ml).
Induction of maturation of monocytes differentiated in presence of IL-10
Monocytes were cultured in presence of GM-CSF plus IL-10 until
day 7. Differentiated monocytes were washed and then activated for 2
days in the presence of TNF-
(2.5 ng/ml) plus LPS (10 ng/ml).
Chemotaxis assay
Cell migration was evaluated using a chemotaxis microchamber technique (48-well Boyden microchamber; Neuroprobe, Pleasanton, CA) (38). Briefly, human recombinant CCL20 and CCL7 were diluted to 1 µg/ml and 100 ng/ml in RPMI 1640 medium, respectively, and were added to the lower wells of the chemotaxis chamber. A total of 105 cells/well in 50 µl RPMI 1640 medium was applied to the upper wells of the chamber, with a standard 5-µm pore polyvinylpyrrolidone-free polycarbonate filter (Neuroprobe) separating the lower wells. The chamber was incubated at 37°C in humidified air with 5% CO2 for 1 h. Then cells that have migrated to the underside of the filter were stained with Fields A and Fields B (BDH Laboratory Supplies, Dorset, England) and counted using an image analyzer (software, Vision Explorer and ETC 3000; Graphtek, Mirmande, France) in two randomly selected low-power fields (magnification x20). Each assay was performed in duplicate, and the results were expressed as the mean SD of migrating cells per two fields.
Transwell (5-µm pore; Costar, Cambridge, MA) experiments were performed to characterize heterogeneous populations. Serial dilutions of chemokines were added to 24-well plates. A total of 5 x 105 cells was added to transwell inserts. Plates were incubated for 1.5 h at 37°C. After removal of the transwell inserts, cells were counted and stained for flow cytometry, to differentiate between CD1a+ and CD14+ cells from either CD34+ HPC or monocytes.
Calcium fluorimetry
Intracellular Ca2+ concentration was measured using the fluorescent probe Indo-1, according to the technique reported by Grynkiewicz et al. (39). In brief, cells were washed in PBS and resuspended at 107 cells/ml in complete RPMI 1640 medium (see above). Then cells were incubated for 45 min at room temperature with 3 µg/ml Indo-1 AM (Molecular Probes, Eugene, OR) in the dark. After incubation, cells were washed and resuspended in HBSS/1% FCS at 107 cells/ml. Before measurement of intracellular Ca2+ concentration, cells were diluted 10-fold in HBSS/10 mM HEPES/1.6 mM CaCl2 preheated at 39°C. Samples were excited at 330 nm with continuous stirring, and the Indo-1 fluorescence was measured as a function of time at 405 nm (dye is complexed with Ca2+) and 485 nm (Ca2+-free medium), in a 810 Photomultiplier Detection System (software, Felix; Photon Technology International, Monmouth Junction, NJ). Results are expressed as the ratio of values obtained at the two emission wavelengths.
Analysis of chemokine receptor expression by FACS
Expression of CCR6 and CCR5 was determined by using the following mAbs conjugated to PE: anti-CCR6 (clone 53103.111; R&D Systems) and anti-CCR5 (clone 2D7; BD PharMingen). For indirect staining, the cells were incubated with biotin-conjugated anti-CCR2 mAb (clone 48607.211; R&D Systems) or unconjugated anti-CCR7 mAb (clone 2H4; BD PharMingen), and subsequently stained with PE-conjugated streptavidin (Jackson ImmunoResearch, West Grove, PA) or with PE-conjugated goat anti-mouse IgM (Jackson ImmunoResearch), respectively. On CD34+-derived DC and monocyte-derived DC, double staining was performed with anti-CD1a FITC (BD PharMingen) and/or anti-CD14 FITC (BD PharMingen).
| Results |
|---|
|
|
|---|
block CCR6 expression on LC precursors through
different mechanisms
We and others have previously shown that CCL20, produced by
epithelial cells, induces the selective migration of LC precursors
(15, 16). To analyze the regulation of LC recruitment in
the periphery during immune responses, we investigated the modulation
of CCR6 expression by different cytokines. First, we have focused our
attention on the effects of IL-4 and IFN-
on CCR6 expression.
CD34+ HPC were cultured in presence of GM-CSF
plus TNF-
plus SCF until day 6 and then cultured only with GM-CSF to
preserve their immaturity.
CCR6 was detected starting at day 6, optimally expressed from day 8 to
10, and progressively lost from day 13 (Fig. 1
A). When IL-4 was added at
day 3 (not shown) or at day 6 on CCR6+ LC
precursors (Fig. 1
A), CCR6 expression was completely
abolished from day 8 to 14. As a consequence, IL-4 added at day 3
induced 7095% suppression of CCL20 responsiveness at day 8, and 95%
from day 10 to 14 (Fig. 1
C). In contrast, the responsiveness
to monocyte chemoattractant protein-3/CCL7 was not affected by IL-4
(Fig. 1
D). Similar effects were observed with IL-13 (not
shown). This down-regulation of CCR6 was most likely the result of the
blockade of LC differentiation, as we previously described
(29), and as illustrated by the down-regulation of
Langerin (Fig. 1
B), without alteration of maturation markers
(CD86, CCR7). In line with this hypothesis, as for LC
differentiation (our unpublished observations), the effect of
IL-4 was reversible (Fig. 2
). Upon
withdrawal of IL-4 for 5 days (day 13), the expression of CCR6 on LC
was recovered at 70% compared with cells that have never been exposed
to IL-4 (Fig. 2
A), and the response to CCL20 was nearly
completely restored (7590%) (Fig. 2
B). While CCR6 protein
was rapidly down-regulated in presence of IL-4, its mRNA was still
present (not shown), offering a possible explanation of the reversible
action of IL-4.
|
|
from day 3 (not shown) or from day 6 on
CCR6+ LC precursors (Fig. 1
also resulted in the suppression of the
migration to CCL20 (see Fig. 2
induced the strong
up-regulation of CD86 and CCR7 (Fig. 1
-induced DC
maturation, as previously reported (40). In line with the
IFN-
-induced maturation, even 5 days after the removal of IFN-
,
the LC were still CCR6 negative (Fig. 2
These observations show that IL-4, through reversible suppression of LC
differentiation, and IFN-
, through induction of irreversible LC
maturation, both block LC migration in response to CCL20 concomitantly
to the loss of CCR6 expression.
Dual role of TGF-
on CCR6 expression depending on the stage of
LC differentiation
TGF-
has been shown to play a critical role in the development
of LC from CD34+ progenitors (25, 29). Thus, we investigated the effect of TGF-
on CCR6
expression during LC development. When TGF-
was added at the
initiation of the culture, no alteration of CCR6 expression was
observed on CD1a+ LC precursors (Fig. 3
A). Also, TGF-
did not
impact on their responsiveness to CCL20 nor to CCL7 in migration assay
(Fig. 3
C). In contrast, the addition of TGF-
at day 6,
which up-regulates Langerin on CCR6+ LC
precursors (Fig. 3
B), induced the down-regulation of CCR6
expression from day 8 to 12 with the concomitant suppression of LC
migration in response to CCL20, without affecting that to CCL7 (Fig. 3
D). When TGF-
was removed at day 8, no recovery of CCR6
expression nor CCL20 responsiveness was observed (not shown).
|
is involved in the development
of the LC phenotype, TGF-
induces the down-regulation of CCR6 during
final LC differentiation. IL-10 up-regulates CCR6 expression on CD34+-derived DC without altering their capacity to differentiate into LC
IL-10 was added at day 6 of the culture, and CCR6
expression was analyzed every 2 days from day 8 to 12 (day 10 is shown
in Fig. 4
A). We found that
IL-10 arrested the cells at the CD14+ and
CD1a+ precursor stage (not shown). Surprisingly,
all these cells expressed high levels of CCR6, with 2- to 4-fold
increase in mean fluorescence intensity compared with
CD34+-derived DC in GM-CSF alone (Fig. 4
A). The effects of IL-10 on other chemokine receptors
involved in DC trafficking were then investigated. CCR2 expression that
is restricted to the CD14+ precursors was
sustained in presence of IL-10 in accordance with the maintenance, in
presence of IL-10, of cells in that stage of differentiation (Fig. 4
A). CCR5 expression was not detected in presence of GM-CSF
alone, and it was slightly induced by IL-10. Regarding CCR7, its
expression was not detected in both conditions.
|
differentiated and acquired characteristic LC markers such as
Langerin and E-cadherin within 4 additional days (Fig. 4These observations show that among the different cytokines tested, IL-10 is the only factor allowing the up-regulation of CCR6 expression during CD34+-derived DC development without altering their capacity to differentiate into LC.
IL-10 selectively induces CCR6 expression and CCL20 responsiveness on differentiated monocytes while preserving their capacity to differentiate into mature DC
These observed effects on CD34+-derived DC
led us to investigate the effect of IL-10 on monocytes and
monocyte-derived DC that do not express CCR6. Monocytes were cultured
in presence of GM-CSF with or without IL-4, in presence or absence of
IL-10 during 7 days. As shown in Fig. 5
A, IL-10 induced CCR6
expression both in presence or absence of IL-4. Then the activity of
CCL20 was assessed by calcium flux (Fig. 6
A) and by chemotaxis assay
(Fig. 6
B), and in accordance with CCR6 expression, the
IL-10-cultured cells responded to CCL20. However, in presence of IL-4,
the IL-10-cultured cells displayed a lower calcium flux and no
migratory capacity in response to CCL20. Of note, shorter time points
have also been tested (1, 3, and 5 days), and no induction of cell
surface expression of CCR6 nor chemotactic response to CCL20 has been
detected under these conditions (not shown). Moreover, the induction of
the expression and the functionality of CCR6 by IL-10 required the
presence of GM-CSF (not shown). In parallel experiments, we could not
detect any effects of TGF-
on monocyte-derived DC.
|
|
After removal of IL-10 and in presence of inflammatory mediators and
bacterial products (TNF-
plus LPS, Fig. 5
C) or T cell
signals (not shown), cells differentiated into mature DC, as
illustrated by the up-regulation of the costimulatory molecules CD83
and CD86, and the induction of the DC maturation marker DC-LAMP. The
phenotype of the mature DC was comparable with cells cultured without
IL-10 (not shown).
These observations show that in presence of IL-10, differentiated monocytes can acquire responsiveness to CCL20 while preserving their capacity to differentiate into mature DC. Moreover, compared with the other main chemokine receptors involved in DC trafficking, the IL-10 effect is selective for CCR6.
| Discussion |
|---|
|
|
|---|
We found that IL-4 and IL-13 block CCR6 expression during LC
development and down-regulate its expression on differentiated LC
precursors, most likely as a consequence of a reversible suppression of
LC differentiation. This observation is in agreement with a recent
study showing that IL-4 down-regulates CCR6 expression on DC
(41). This inhibitory effect of IL-4 may explain the
absence of CCR6 on DC differentiated from monocytes in presence of
GM-CSF plus IL-4 (42, 43). However, these results may
appear in contrast with a recent report showing that monocytes cultured
in presence of GM-CSF, IL-4, and TGF-
express CCR6 and respond to
CCL20 (44).
Several lines of evidences suggest that IL-4 amplifies the Th2
responses by inducing both receptors (CCR3, CCR4, and CCR8
(45)) and ligands (CCL22 and CCL17 (46, 47))
involved in Th2 cell recruitment and by blocking the expression of
ligands for Th1-selective receptors (CXCL9, CXCL10, and CXCL11
(48, 49)). The presently described effect of IL-4 on CCR6
expression may be linked to an amplification of Th2 responses. It is
tempting to speculate that during Th2 responses, the local production
of IL-4 might prevent the recruitment of LC at site of injury, and the
induction of immune response other than Th2. However, we also found
that IFN-
blocks the expression of CCR6 as well as CCL20
responsiveness. Unlike IL-4, IFN-
amplify Th-1 responses by inducing
CXCR3 in T cells (50) as well as its ligands CXCL9,
CXCL10, and CXCL11 in many cell types (51), and by
preventing the expression of CCR4 ligands (50). Thus, LC
recruitment might also be suppressed during ongoing Th1-type immune
responses. This may appear in contrast with our previous observation of
CCL20 up-regulation in close association with infiltrating LC and
memory T cells in lesional skin from psoriasis (15, 52), a
pathology that is associated with a Th1 profile (production of IL-2,
IL-12, and IFN-
). In the present study, we have demonstrated that
the ability of IFN-
to induce the irreversible loss of CCR6
expression is linked to its effect on DC maturation, as shown by the
up-regulation of costimulatory molecules (40) and the
induction of CCR7 expression. Besides, this result is in line with the
observation that maturing DC-LAMP+ LC are present
in lesional psoriatic skin (15). Thus, IFN-
might
switch chemokine responsiveness and allow DC to respond to other
chemokines such as CCL19 and CCL21 involved in the constitutive DC
trafficking into lymphoid organs. Additionally, the observed CCR6
down-regulation induced by IFN-
and also by IL-4 may act as a stop
signal to prevent the recruitment of additional LC precursors, and thus
attenuate the local inflammation, when the cytokines leak into the
circulation.
Because the effects of IL-4 and IFN-
on CCR6 down-regulation may
suggest that LC are involved in immune-type reactions different from
polarized Th1/Th2 responses, we have investigated the effects of
TGF-
and IL-10, cytokines recognized for their role in the
development of regulatory T cells (53). Surprisingly, we
found that IL-10 maintains the expression of CCR6 on precursor cells
that preserve their capacity to differentiate into LC. So, this data
clearly indicate that IL-10-treated DC are not committed in a defined
pathway, nor completely differentiated. This observation might be
related to the previously described arrest of LC maturation by IL-10
(30). Furthermore, we observed that IL-10 up-regulates
CCR6 expression on monocyte-derived DC, and this receptor is
functional, as demonstrated by the capacity of IL-10-treated cells to
migrate in response to CCL20. The investigation of other important
chemokine receptors involved in DC trafficking (CCR2, CCR5, and CCR7)
demonstrated that the observed effect of IL-10 was selective for CCR6.
Importantly, these IL-10-treated cells were not terminally
differentiated macrophages, as they had the capacity to differentiate
into mature DC upon inflammatory or T cell signals. Seven days of
culture in presence of GM-CSF and IL-10 were required to optimally
induce CCL20 responsiveness on monocytes, suggesting that the effect of
IL-10 on CCR6 expression by monocyte-derived DC is not optimal as a
possible consequence of the inhibitory effect of IL-4 on CCR6
expression. As monocytes have been shown to differentiate into DC in
absence of IL-4 within 2 days following a transendothelial migration
(54, 55), IL-10 may under some environmental conditions
allow monocytes (or DC precursors) to acquire the capacity to
reach the epithelium in response to CCL20. Furthermore, in
contrast to the inhibitory effect of IL-10 on CCL20 secretion by
monocytes (56), CCL20 expression by epithelial cells,
which are the main in vivo source, was not decreased by IL-10 (not
shown).
Unexpectedly, when
CCR6+CD1a+ LC precursors
were exposed to TGF-
, a cytokine involved in LC development, a
profound reduction of CCR6 expression was observed. This may appear in
contradiction with the described effects of TGF-
on CCR6
up-regulation on monocyte-derived DC (44, 57). However,
blocking endogenous TGF-
prevents LC development (29)
and CCR6 expression (not shown), suggesting that TGF-
is involved in
CCR6 expression, as a part of a program of LC differentiation from
CD34+ progenitors or monocytes. The
down-regulation of CCR6 by TGF-
on CCR6+ LC
precursors might reflect the terminal differentiation into epithelial
LC induced by TGF-
. Thus, the control of the epithelial colonization
by LC might be the result of combined action of TGF-
and CCL20
expressed at a very low level in normal skin (16, 52).
CCL20 has been reported to be expressed in airway (42, 58, 59) and intestinal (19, 60, 61) mucosa. As both
TGF-
and IL-10 are key regulators of mucosal immunity, one might
speculate that they cooperate to increase the efficiency of LC
recruitment at epithelial surfaces. IL-10 maintains CCR6 expression on
LC precursors, expanding the window of CCL20 action and thus the
efficiency of recruitment. When reaching the epithelium, the local
TGF-
will then drive their final differentiation and arrest them in
the epithelial layers by down-regulating CCR6 expression. In this
context, TGF-
has been shown to freeze in vitro generated LC into an
epithelial state (62).
In addition, CCL20 is highly expressed by numerous tumors and cell
lines: pancreas, papillary, renal, and breast carcinoma and metastasis
(Refs. 63, 64, 65 and our unpublished observations), in
which the production of both IL-10 and TGF-
has been documented.
Thus, IL-10 and TGF-
produced in the tumor microenvironment may have
an important role not only in the differentiation/maturation of DC, but
also in modulating the recruitment of selective DC precursors. In this
context, IL-10-treated DC have been shown to induce tolerance
(32).
CCR6 has been shown to be preferentially expressed on memory T cells
with both skin- and gut-homing properties (17, 18). In
addition, CCL20 has been shown to mediate the migration of intestinal
epithelium 
T cells (19). We have reported the
up-regulation of CCL20 in lesional psoriatic skin, in close vicinity of
LC and memory T cells (15, 52). Altogether, these
observations suggest that CCL20 may have specific role in regulating
epithelial immunity through both the recruitment of LC precursors and
memory T cells with epithelial tropism.
Acting on T lymphocytes, IL-4, IFN-
, IL-10, and TGF-
are involved
in cross-regulation between Th-1, Th-2, and regulatory immune
responses. In the present study, we add a further level of complexity
with cytokines that differentially regulate the recruitment of LC at
epithelial surface through the regulation of CCR6 expression by those
cells. While Th1 (i.e., IFN-
) and Th2 cytokines (i.e., IL-4 and
IL-13), by down-regulating CCR6 expression, may attenuate ongoing
immune responses, regulatory cytokines (i.e., IL-10 and TGF-
) have
the opposite effect, and thus may amplify those responses. Along with
this hypothesis, we recently obtained evidence that
CD34+-derived LC allow the development of
CD4+ T cells producing IL-10, while the other
populations (CD14+-derived and monocyte-derived
DC) lack this capacity (our unpublished observations). These
IL-10-secreting CD4+ T cells might be related to
the described regulatory T cells. Collectively, these observations
suggest that through their actions on LC, TGF-
, IL-10, and CCL20
contribute to the regulatory immune responses at epithelial
surfaces.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Abbreviations used in this paper: DC, dendritic cell; HPC, hemopoietic progenitor cell; LAMP, lysosome-associated membrane glycoprotein; LC, Langerhans cell; rh, recombinant human; SCF, stem cell factor. ![]()
Received for publication May 7, 2001. Accepted for publication September 10, 2001.
| References |
|---|
|
|
|---|
. II. Functional analysis. Blood 90:1458.
+ and CD8
- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 189:587.
is involved in the constitutive trafficking of epidermal Langerhans cells. J. Exp. Med. 190:1755.
. J. Immunol. 162:186.
and TGF-
responses regulate the occurrence of mucosal inflammation. Immunol. Today 18:61.[Medline]
-producing cells from naive CD4+ T cells: IL-4 and IFN-
have opposing effects, while TGF-
positively regulates its own production. J. Immunol. 160:5719.
1 promotes in vitro development of dendritic cells from CD34+ hemopoietic progenitors. J. Immunol. 157:1499.[Abstract]
1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 90:1425.
. J. Exp. Med. 179:1109.
and IL-4 in the development of Langerhans cells and non-Langerhans dendritic cells from CD34+ progenitors. J. Leukocyte Biol. 66:781.[Abstract]
and interleukin-10 inhibit antigen presentation by Langerhans cells for T helper type 1 cells by suppressing their CD80 (B7-1) expression. Eur. J. Immunol. 26:648.[Medline]
. J. Exp. Med. 184:695.
strongly potentiates interleukin-3 and granulocyte-macrophage colony-stimulating factor-induced proliferation of human CD34+ hematopoietic progenitor cells. Blood 75:2292.
, and additional cytokines: antagonistic effects of IL-4 and IFN-
and selective involvement of TNF-
receptor-1. Immunology 91:553.[Medline]
-chemokine receptor CCR6 in dendritic cells mediated by TNF-
and IL-4. J. Leukocyte Biol. 66:837.[Abstract]
from lung dendritic cells. J. Exp. Med. 186:825.
and is highly expressed in human dendritic cells. J. Exp. Med. 186:837.
1 express functional C-C chemokine receptor 6. J. Immunol. 163:1737.
and/or IL- 2 in murine peritoneal macrophages. J. Immunol. 148:1725.[Abstract]
(MIG), IFN-inducible T cell
chemoattractant (I-TAC), and IFN-
-inducible protein-10 (IP-10) chemokines by human neutrophils. J. Immunol. 162:4928.
/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164:6621.
and MIP-3
. J. Immunol. 158:1033.[Abstract]
1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J. Immunol. 164:2285.
-chemokine. Blood 89:3315.
, MIP-3
, and secondary lymphoid organ chemokine. J. Exp. Med. 191:1381.
1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 162:4567.
/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 81:650.[Medline]
This article has been cited by other articles:
![]() |
C. Hastie, J. R. Masters, S. E. Moss, and S. Naaby-Hansen Interferon-{gamma} Reduces Cell Surface Expression of Annexin 2 and Suppresses the Invasive Capacity of Prostate Cancer Cells J. Biol. Chem., May 2, 2008; 283(18): 12595 - 12603. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. de Gruijl, C. C. Sombroek, S. M. Lougheed, D. Oosterhoff, J. Buter, A. J. M. van den Eertwegh, R. J. Scheper, and H. M. Pinedo A Postmigrational Switch among Skin-Derived Dendritic Cells to a Macrophage-Like Phenotype Is Predetermined by the Intracutaneous Cytokine Balance. J. Immunol., June 15, 2006; 176(12): 7232 - 7242. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gautier, B. de Saint-Vis, B. Senechal, J.-J. Pin, E. E.M. Bates, C. Caux, F. Geissmann, and P. Garrone The Class 6 Semaphorin SEMA6A Is Induced by Interferon-{gamma} and Defines an Activation Status of Langerhans Cells Observed in Pathological Situations Am. J. Pathol., February 1, 2006; 168(2): 453 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Guess and D. J. McCance Decreased Migration of Langerhans Precursor-Like Cells in Response to Human Keratinocytes Expressing Human Papillomavirus Type 16 E6/E7 Is Related to Reduced Macrophage Inflammatory Protein-3{alpha} Production J. Virol., December 1, 2005; 79(23): 14852 - 14862. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gombert, M.-C. Dieu-Nosjean, F. Winterberg, E. Bunemann, R. C. Kubitza, L. Da Cunha, A. Haahtela, S. Lehtimaki, A. Muller, J. Rieker, et al. CCL1-CCR8 Interactions: An Axis Mediating the Recruitment of T Cells and Langerhans-Type Dendritic Cells to Sites of Atopic Skin Inflammation J. Immunol., April 15, 2005; 174(8): 5082 - 5091. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kleinewietfeld, F. Puentes, G. Borsellino, L. Battistini, O. Rotzschke, and K. Falk CCR6 expression defines regulatory effector/memory-like cells within the CD25+CD4+ T-cell subset Blood, April 1, 2005; 105(7): 2877 - 2886. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Flaishon, S. Becker-Herman, G. Hart, Y. Levo, W. A. Kuziel, and I. Shachar Expression of the chemokine receptor CCR2 on immature B cells negatively regulates their cytoskeletal rearrangement and migration Blood, August 15, 2004; 104(4): 933 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Honczarenko, Y. Le, A. M. Glodek, M. Majka, J. J. Campbell, M. Z. Ratajczak, and L. E. Silberstein CCR5-binding chemokines modulate CXCL12 (SDF-1)-induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor Blood, September 18, 2002; 100(7): 2321 - 2329. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Guironnet, C. Dezutter-Dambuyant, C. V. N. Bechetoille, D. Schmitt, and J. Peguet-Navarro Antagonistic effects of IL-4 and TGF-{beta}1 on Langerhans cell-related antigen expression by human monocytes J. Leukoc. Biol., May 1, 2002; 71(5): 845 - 853. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takahara, Y. Omatsu, Y. Yashima, Y. Maeda, S. Tanaka, T. Iyoda, B. Clusen, K. Matsubara, J. Letterio, R. M. Steinman, et al. Identification and expression of mouse Langerin (CD207) in dendritic cells Int. Immunol., May 1, 2002; 14(5): 433 - 444. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |